The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Looks like Toms keeping himself busy . Another talk lined up for the 16th: https://virtual.digileaders.com/speakers/tom-oakley/
CE approval at anytime , and already speaking to other trusts, I think we could have multiple RNS's on the next few weeks.
Once this is rolled out to NHS, there's a private sector too + other industries such as the Vet field which they already said there's interest. And then the global market part of it too , I think this share has a long way to go. Could be absolutely massive - 50p is easily on the cards , and maybe more if they play it right
RNS had landed ;)
"The Company is in advanced discussions with NHS pilot sites whilst additionally pursuing a number of commercial opportunities within and outside the NHS, and hopes to commence Bleepa® pilot schemes in the near future."
While nothing officially signed, looks very promising that they are in advanced talks.
Also to note, while the WhatsApp messages may be encrypted, "Medical images are often shared as part of these chats as photos of computer screens, and do not meet diagnostic clinical standards". This is the massive difference between sharing photos using WhatsApp and using the "only communication tool to be a CE marked medical device" ;)
Agreed. With companies now starting to be fined because of GDPR, it's far cheaper for the NHS to adopt this then risk being fined. This could be the tipping point major players need to be able to sign that dotted line.
"The Directors believe this new product will also be the only communication tool to be a CE marked medical device." - This itself is a strong USP that will undoubtedly increase sales.
Also it's worth pointing out that they have increased revenues by 23% this financial year - which is a very good growth rate. Then look at the previous trading update: "The investment in new hires for Cadran, along with the agreement with Future Processing, signed in January 2019, to accelerate Feedback Medical's technology development and innovation, has increased the Company's cost base, the principal benefit of which will not be realised until the next financial year. "
This was before they decided to move to a SaaS type sales platform which they believe is more lucrative. If all goes according to plan, I'd expect a minimum of 50% growth in revenues by the next trading update. And this is before they announce what they have planned for TexRad.
I can see massive growth in FDBK in the next 3 months - 2 years, and I for sure will be topping up over time.
Research versions of TexRAD - £25-£50k + 20% annual maintenance, and Cadran at £150k a pop - those are some juicy numbers, and Feedback have already made some sales in the past! With those sales + research papers it's proven tech.
With the intention to move more to the commercial end, I think we can expect bigger sales and even bigger numbers.
FDBK has typically been a very slow stock with very little movement, and with no real news for a long while it's odd to see such a big uptick in trades and holdings - something leaked? New contracts? JV? Take over? Whatever it is, it's getting exciting!